Inflarx N.V. (NASDAQ:IFRX) had a decrease of 1.57% in short interest. IFRX’s SI was 231,600 shares in February as released by FINRA. Its down 1.57% from 235,300 shares previously. With 11,900 avg volume, 20 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 3.2%. The stock increased 5.81% or $1.91 during the last trading session, reaching $34.81. About 90,681 shares traded or 1.53% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since February 28, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results
Peoples Financial Services Corp increased Phillips 66 (PSX) stake by 50.71% reported in 2018Q3 SEC filing. Peoples Financial Services Corp acquired 3,360 shares as Phillips 66 (PSX)’s stock declined 22.04%. The Peoples Financial Services Corp holds 9,986 shares with $1.13 million value, up from 6,626 last quarter. Phillips 66 now has $44.52 billion valuation. The stock decreased 0.20% or $0.2 during the last trading session, reaching $97.64. About 1.88M shares traded. Phillips 66 (NYSE:PSX) has declined 9.22% since February 28, 2018 and is downtrending. It has underperformed by 9.22% the S&P500. Some Historical PSX News: 08/03/2018 – PHILLIPS 66 ALLIANCE LOUISIANA REFINERY BEGINS REFORMER, HYDROTREATER OVERHAUL; 26/04/2018 – Skinny and sweet: U.S. refiner earnings depend on the oil diet; 25/04/2018 – Phillips 66 expected to post earnings of 89 cents a share – Earnings Preview; 27/04/2018 – Phillips 66 1Q EPS $1.07; 05/05/2018 – Praise for Phillips 66 — Berkshire Hathaway Annual Meeting; 17/04/2018 – Phillips 66’s JV Borger, Texas gasoline units due back next week; 27/04/2018 – PHILLIPS 66 QTRLY TOTAL REVENUES AND OTHER INCOME $24,046 MLN VS $23,712 MLN; 16/05/2018 – Phillips 66 Presenting at Conference Tomorrow; 27/04/2018 – Phillips 66 1Q Operating Cash Flow $488 Million; 17/04/2018 – Phillips 66 Reports Equipment Issues at Sweeny Refinery in Texas
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – Nasdaq” on February 27, 2019, also Globenewswire.com with their article: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” published on February 14, 2019, Globenewswire.com published: “Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx NV, Enerplus, and ManTech International â€” Emerging Consolidated Expectations, Analyst Ratings – GlobeNewswire” on February 25, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Dassault Aviation: Financial Release – 2018 annual results – Nasdaq” published on February 28, 2019 as well as Nasdaq.com‘s news article titled: “Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK – Nasdaq” with publication date: February 28, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $893.30 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Among 9 analysts covering Phillips 66 (NYSE:PSX), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Phillips 66 had 11 analyst reports since September 7, 2018 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, November 20. The firm has “Buy” rating given on Thursday, December 20 by Jefferies. The company was upgraded on Friday, November 16 by U.S. Capital Advisors. The firm has “Overweight” rating given on Thursday, January 10 by PiperJaffray. The firm has “Overweight” rating by JP Morgan given on Tuesday, October 30. Barclays Capital upgraded it to “Equal-Weight” rating and $128 target in Wednesday, October 3 report. The rating was maintained by Wells Fargo with “Outperform” on Monday, October 29. Raymond James maintained Phillips 66 (NYSE:PSX) rating on Monday, October 29. Raymond James has “Outperform” rating and $135 target. Raymond James maintained Phillips 66 (NYSE:PSX) on Monday, December 31 with “Outperform” rating. The rating was maintained by Citigroup on Friday, September 7 with “Neutral”.
Investors sentiment increased to 1.19 in 2018 Q3. Its up 0.03, from 1.16 in 2018Q2. It is positive, as 35 investors sold PSX shares while 356 reduced holdings. 113 funds opened positions while 351 raised stakes. 305.42 million shares or 2.74% less from 314.02 million shares in 2018Q2 were reported. Price T Rowe Inc Md has 0.08% invested in Phillips 66 (NYSE:PSX). 161,913 are owned by Todd Asset Mngmt Lc. Williams Jones & Associate Limited Liability Corp accumulated 3,489 shares. Checchi Advisers Ltd Com has 5,194 shares for 0.07% of their portfolio. Bridges Mgmt Incorporated invested in 0.01% or 2,250 shares. Moreover, Of Vermont has 0.03% invested in Phillips 66 (NYSE:PSX) for 3,520 shares. Fire Grp accumulated 5,029 shares. First Personal holds 0.05% of its portfolio in Phillips 66 (NYSE:PSX) for 1,357 shares. Massachusetts-based Eastern Financial Bank has invested 0.02% in Phillips 66 (NYSE:PSX). United Automobile Association owns 0.15% invested in Phillips 66 (NYSE:PSX) for 530,164 shares. Eqis Cap Mngmt holds 0.09% or 12,405 shares in its portfolio. Navellier And Assoc Inc stated it has 41,613 shares or 0.61% of all its holdings. 458 were reported by Fincl Engines Advsrs Ltd Liability Corporation. Korea Inv owns 206,523 shares. 11,061 are held by Cleararc Capital.
More notable recent Phillips 66 (NYSE:PSX) news were published by: Seekingalpha.com which released: “Phillips 66: An Extraordinary Energy Logistics Company – Seeking Alpha” on February 27, 2019, also Seekingalpha.com with their article: “Phillips 66: Another Success Story Among Refiners – Seeking Alpha” published on February 28, 2019, Seekingalpha.com published: “Phillips 66 Is On My Watchlist – Seeking Alpha” on February 11, 2019. More interesting news about Phillips 66 (NYSE:PSX) were released by: Seekingalpha.com and their article: “Phillips 66 Posts Stellar 2018 Performance But Tricky Road Ahead – Seeking Alpha” published on February 10, 2019 as well as Globenewswire.com‘s news article titled: “New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing â€” Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: February 13, 2019.
Since November 20, 2018, it had 1 insider buy, and 0 insider sales for $1.98 million activity. The insider FERGUSON J BRIAN bought 21,500 shares worth $1.98 million.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.